14. März 2021 – The EMA has completed its review on the use of the monoclonal antibodies bamlanivimab and etesevimab to treat patients with COVID-19. The Agency concluded that bamlanivimab and etesevimab can be used together to treat confirmed COVID-19 in patients who do not require supplemental oxygen and who are at high risk of their COVID-19 disease becoming severe. The Agency also looked at the use of bamlanivimab alone and concluded that, despite uncertainties around the benefits of monotherapy, it can be considered a treatment option.

For more information, see here.